EGFR and hepatocellular carcinoma: This involves direct interaction with the 3′-UTR of ABCB1 and suppression of the EGFR-related phosphorylation of the ERK1/2 pathway, ultimately giving rise to increased sensitivity of hepatoma cells to doxorubicin (Zhao et al., 2018).